Biotechnology

Medolife Rx Starts Distribution of Its Products in Canada

February 2, 2021 8:56 AM

BURBANK, CA / ACCESSWIRE / February 2, 2021 / Medolife Rx, Inc., ("Medolife") a majority owned subsidiary of Quanta, Inc. (OTC PINK:QNTA), announced today that it began major distribution of its Quanta Muscle Rub™ products in Canada in collaboration with Better Health Sciences, Inc. During a pilot sale campaign, Better Health Sciences received exceptionally positive feedback from its customers on the Quanta Muscle Rub™, a topical product...

Read more

Havn Life Announces Strategic Clinical Trial Partnership with HealthTech Connex Inc.

February 2, 2021 8:00 AM

Havn Life to supply psychedelic compounds for clinical trials launched by neuroscience and technology leader HealthTech Connex VANCOUVER, BC / ACCESSWIRE / February 2, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce a strategic...

Read more

Viewpoint Molecular Targeting(TM) Presents Positive Preclinical Data from VMT01 Program at the 2021 SNMMI Mid-Winter Meeting

February 1, 2021 10:00 AM

- Positive preclinical data demonstrating that a single dose of [212Pb]-VMT01 significantly enhanced response to immune checkpoint inhibitors relative to checkpoint inhibitor treatment alone with a 43% rate of complete response in a B16 melanoma tumor model in mice - - Company plans to advance its VMT01 program into Phase 1 imaging study, to be followed by Phase 1/2a therapy study for the treatment of metastatic melanoma - CORALVILLE, IA /...

Read more

Wuhan General Group Posts FY19 and FY20 Results

February 1, 2021 9:40 AM

CAPE TOWN, SA / ACCESSWIRE / February 1, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce today that the Company has released its financial results for the full year ended December 31, 2019 and 2020 by posting on the OTC Market website. Please visit www.otcmarkets.com to view the financials and...

Read more

Enzolytics Announces The Discovery Of Seven Newly Identified Conserved Target Sites On The HIV Virus

February 1, 2021 9:00 AM

Company begins process of identifying conserved/immutable target sites on SARS-CoV-2 (the CoronaVirus) and other developments COLLEGE STATION, TX / ACCESSWIRE / February 1, 2021 / Enzolytics, Inc. (OTC PINK:ENZC)(the "Company") today announced it has identified seven additional conserved, expectedly immutable sites on the HIV virus against which it plans to produce targeted anti-HIV monoclonal antibodies. The Company's primary anti-HIV...

Read more

MJTV Joint Venture Partner Genesis Botanical Signs Contract For 40 Acres Of Hemp Biomass For Its CBD Extraction Facility As Well As Further Expansion

February 1, 2021 9:00 AM

CHEYENNE, WY / ACCESSWIRE / February 1, 2021 / MJ Biotech, Inc. (OTC PINK:MJTV), is pleased to announce, its wholly-owned Subsidiary, New England Biotech's partner Genesis Botanical, signed its first contract with a Maine farmer to provide 40 acres of hemp biomass for extraction for the 2021 farming season. Company executives met with the farmer and his team at their indoor facility to discuss and advise on the different varieties of hemp to...

Read more

NeutriSci Closes Financing

January 29, 2021 6:45 PM

VANCOUVER, BC / ACCESSWIRE / January 29, 2021 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSXV:NU)(OTCQB:NRXCF)(FRANKFURT:1N9), an innovative technology company developing products for the nutraceutical industry, is pleased to announce that it has closed a non-brokered private placement (the "Placement") in which it raised gross proceeds of $370,050. This Placement consisted of 2,467,000 units (the "Units") of the Company...

Read more

Tetra Bio-Pharma Announces FDA Clearance on IND, allowing U.S. Reborn1(TM) Clinical Trial to Commence

January 29, 2021 6:30 AM

OTTAWA, ON / ACCESSWIRE / January 29, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development announced today that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application, allowing Tetra to initiate its QIXLEEFTM Reborn1TM clinical trial in cancer patients with breakthrough pain. "This is really...

Read more

Helix Biopharma Corp. Reports Voting Results

January 28, 2021 5:40 PM

RICHMOND HILL, ON / ACCESSWIRE / January 28, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced the voting results of the Company's annual and special meeting of shareholders held on January 28, 2021 (the "Meeting"). In accordance with section 11.3 of...

Read more

MJTV Joint Venture Partner Genesis Botanical Signs Contract for 40 Acres of Hemp Biomass for Its CBD Extraction Facility as Well as Further Expansion

January 27, 2021 5:45 PM

CHEYENNE, WY / ACCESSWIRE / January 27, 2021 / MJ Biotech, Inc. (MJTV), is pleased to announce, its wholly-owned Subsidiary, New England Biotech's partner Genesis Botanical, signed its first contract with a Maine farmer to provide 40 acres of hemp biomass for extraction for the 2021 farming season. Company executives met with the farmer and his team at their indoor facility to discuss and advise on the different varieties of hemp to be grown....

Read more

Viewpoint Molecular Targeting(TM) to Present at the 2021 SNMMI Mid-Winter Meeting

January 27, 2021 10:00 AM

CORALVILLE, IA / ACCESSWIRE / January 27, 2021 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced its abstract has been selected for oral presentation at the 2021 SNMMI Mid-Winter Meeting, being held virtually January 28-31, 2021. Summarized below is the abstract that will be...

Read more

Financier Sheldon Inwentash Joins Wuhan General Group as Strategic Advisor

January 27, 2021 9:00 AM

CAPE TOWN, SA / ACCESSWIRE / January 27, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce today that the Company has entered into an advisory agreement with Sheldon Inwentash. Sheldon is well-known in the North American capital markets for his investment prowess and strategies, for...

Read more

EV Biologics Has Engaged Foley & Lardner LLP for Legal Counsel in Intellectual Property

January 26, 2021 8:15 AM

CHEYENNE, WY / ACCESSWIRE / January 26, 2021 / EV Biologics Corp, OTC: YECO today announced that it has entered into an engagement agreement with the esteemed international law firm, Foley & Lardner LLP, est. 1842. The firm is at the top of Intellectual Property Law in Biotechnology and Organics and has a specialty in stem cell and extracellular vesicle technology. EV Biologics CEO, Daniel Mckinney said "with Foley & Lardner, we have engaged...

Read more

Edesa Biotech to Study Its Investigational Drug as Potential Rescue Therapy

January 26, 2021 7:30 AM

TORONTO, ON / ACCESSWIRE / January 26, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received regulatory approval from the U.S. Food and Drug Administration (FDA) and Health Canada to add a sub-study to its ongoing Phase 2/Phase 3 clinical study of its investigational drug, EB05, for the treatment of Acute Respiratory Distress Syndrome (ARDS) - the leading cause of death in COVID-19 patients. The...

Read more

Applied UV Receives Notification of Patent Allowance from European Patent Office for Pathogen Destroying Devices

January 25, 2021 12:30 PM

Adds to Company's Patent Protecting Disinfection Technology Portfolio Addressing Global Challenge of HAI's and Pathogen Spread in Public Spaces MOUNT VERNON, NY / ACCESSWIRE / January 25, 2021 / Applied UV, Inc. (NasdaqCM:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") to destroy pathogens safely, thoroughly, and automatically, announced that the...

Read more

Exceltox Laboratories, LLC RECEIVES ACCREDITATION FROM COLLEGE OF AMERICAN PATHOLOGISTS

January 22, 2021 3:30 PM

IRVINE, CA / ACCESSWIRE / January 22, 2021 / The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Exceltox Laboratories, Irvine, based on results of a recent on-site inspection as part of the CAP's Accreditation Programs. Exceltox Laboratories is a CLIA-certified laboratory offering advanced clinical and toxicology testing services. Located in Irvine, California, currently they offer services...

Read more

Integrated BioPharma Announces Upgrade to OTCQX

January 22, 2021 9:00 AM

HILLSIDE, NJ / ACCESSWIRE / January 22, 2021 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP"), upgraded to the OTCQX® Best Market from OTCQB® Venture Market as of today. OTC Markets Group Inc. (OTCQX:OTCM) is an operator of financial markets for 11,000 U.S. and global securities. Integrated BioPharma, Inc. begins trading today on OTCQX under the symbol "INBP." U.S. investors can find current financial disclosure and...

Read more

Havn Life Sciences Announces Inclusion in First Psychedelic Exchange Traded Fund

January 22, 2021 8:00 AM

VANCOUVER, BC / ACCESSWIRE / January 22, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life") a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that it will be included in the First Psychedelics Exchange Traded Fund ("ETF"). The ETF will begin traded on the Neo Exchange on January 26,...

Read more

MJ Biotech, Inc. (MJTV), Subsidiary, Joint Venture Partner Genesis Botanical Research, Begins Construction of CBD Extraction Facility

January 21, 2021 7:00 AM

CHEYENNE, WY / ACCESSWIRE / January 21, 2021 / MJ Biotech Inc. (MJTV) is pleased to announce that it's subsidiary New England Biotech's partner Genesis Botanical, has begun construction of the CBD Extraction facility after securing a location. The facility will be owned by MJTV's wholly owned subsidiary, New England Biotech. The site of the facility in Sagadahoc County, in Mid-Coast Central Maine on agricultural land and governmentally...

Read more

Edesa Biotech to Join Panel Discussion at Government COVID-19 Event

January 20, 2021 7:45 AM

TORONTO, ON / ACCESSWIRE / January 20, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to participate in a virtual event organized by Clinical Trials Ontario in collaboration with the Bureau du Québec à Toronto and the Canadian and International Innovation Partnerships Directorate. As part of a government and industry panel, Dr....

Read more